

Remarks

Claims 1-4 and 8-11 are pending in this application. Claims 3 and 8-10 have been amended. Claim 11 has been added. Claims 5, 6 and 7 have been cancelled. No new matter has been added.

By way of this preliminary amendment, claims 3 and 8-10 have been amended. These claim amendment are being made solely for purposes of placing the claims in a format appropriate for U.S. prosecution. Applicants submit that the amendments do not change the scope of the claims as originally filed. Such amendments are therefore made to address formalities in the claim format and are not related to the patentability of the subject matter of the claims. No new matter was added by way of these claim amendments.

The subject matter of newly added claim 11 is disclosed in the application as filed in original claim 7.

In view of the above amendments and arguments, this application is deemed to be in a form suitable for US prosecution.

Respectfully submitted,

Br. Tilman

Dr. Tilman Breitenstein
Limited Recognition Under 37 CFR § 11.9(b)
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175

Phone: (203) 812-2226
Date: 04/19/2005